Platform for Massively Parallel Selection of Aptamer Ligands
Small Business Information
BIOTEX, INC., 8058 EL RIO ST, HOUSTON, TX, 77054
AbstractDESCRIPTION (provided by applicant): Aptamers have emerged as one of the most promising classes of drug leads and diagnostic ligands presently available. Aptamers, nucleic acid ligands derived from large combinatorial libraries, typically have affinities a nd specificities that rival antibodies, yet they have a number of significant advantages for therapeutic and diagnostic applications. Unfortunately, the present process for aptamer development is low-throughput and tedious as DNA or RNA libraries are scree ned against only a single target. This project focuses on developing the methods and tools to allow large combinatorial to be screened against arrays of thousands of proteins simultaneously. Such protein arrays are increasing available with content of high therapeutic and diagnostic value. The key to achieving this is developing the necessary steps to decipher which aptamers (once selected) correspond to which target. So-called next generation sequencing will greatly enable the proposed process coupled wi th the necessary sequence- tagging approaches developed in this project. Once our massively parallel aptamer selection process is developed, we will be in a position to create high affinity aptamer ligands to thousands of proteins in roughly 1 week. The developed ligands will can then be further characterized as promising drug candidates, diagnostic labels, and other research applications. PUBLIC HEALTH RELEVANCE: A recent white paper by the US Federal Drug Administration finds that there exists a critic al problem in bringing novel drugs to market, something the FDA describes as the 'pipeline problem'. According to this and other reports drug companies spend an average of 0.8-1.7 billion dollars on the discovery, development and approval of any one indiv idual drug. To make matters worse, the time from the initial testing of a drug candidate and to its eventual marketing can take up to 20 years. Thus, the FDA report strongly urges the incorporation of novel quantitative predictive tools for the assessment of safety and efficacy of new drug leads and diagnostic ligands early in the drug development process. This project provides for the parallel development and evaluation of enormous combinatorial libraries of DNA or RNA 'aptamers' against of thousands of pr otein targets of potential 'druggable' interest. If successful, the technology could provide for unprecented throughput of drug leads and diagnostic ligands.
* information listed above is at the time of submission.